Blog
RSS FeedPosted by Michael Wonder on 15 Jul 2016
Gilead receives approval in Canada for Epclusa (sofosbuvir/velpatasvir), the first once-daily pan-genotypic (genotypes 1-6) single tablet regimen for the treatment of chronic hepatitis C
14 July 2016 - Two week treatment with Epclusa provides high cure rates for all six hepatitis C genotypes. ...
Posted by Michael Wonder on 25 May 2016
Health Canada approves Daklinza (daclatasvir dihydrochloride) for difficult-to-treat hepatitis C patient populations
24 May 2016 - Daklinza is approved in Canada in combination with other agents for the treatment of chronic hepatitis C ...